000 01272 a2200373 4500
005 20250515061920.0
264 0 _c20070911
008 200709s 0 0 eng d
022 _a0007-0963
024 7 _a10.1111/j.1365-2133.2007.07762.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSelenko-Gebauer, N
245 0 0 _aEfalizumab in routine use: a clinical experience.
_h[electronic resource]
260 _bThe British journal of dermatology
_cApr 2007
300 _a1-6 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAcute Disease
650 0 4 _aAntibodies, Monoclonal
_xadverse effects
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aAustria
650 0 4 _aCD11a Antigen
_ximmunology
650 0 4 _aHumans
650 0 4 _aImmunosuppressive Agents
_xadverse effects
650 0 4 _aPatient Education as Topic
650 0 4 _aPatient Selection
650 0 4 _aPsoriasis
_xdrug therapy
650 0 4 _aRecurrence
650 0 4 _aSkin
_ximmunology
650 0 4 _aTreatment Outcome
700 1 _aKarlhofer, F
700 1 _aStingl, G
773 0 _tThe British journal of dermatology
_gvol. 156 Suppl 2
_gp. 1-6
856 4 0 _uhttps://doi.org/10.1111/j.1365-2133.2007.07762.x
_zAvailable from publisher's website
999 _c16926332
_d16926332